At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 458 enrolled
Drug / intervention
Reldesemtiv +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
In Brief
A Phase 2 clinical trial evaluating Reldesemtiv and Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 458 participants across 64 sites in 6 countries.
Detailed Summary
The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesAustralia, Canada, Ireland, Netherlands, Spain, United States
CollaboratorsAstellas Pharma Inc
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJul 2017
Primary CompletionMar 2019
TodayJul 2026
First PostedMay 19, 2017
Enrollment StartJul 24, 2017
Primary CompletionMar 7, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.1 years ago
Interventions
Reldesemtivdrug
Oral tablet
Placebodrug
Oral tablet